Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Hematology
Chronic Myeloid Leukemia Clinical Trials
A listing of Chronic Myeloid Leukemia medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama Comprehensive Cancer Center University of Alabama
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Muscle Shoals : Northwest Alabama Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Arizona
Sedona : Arizona Oncology Associates, PC - NAHOA
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Tucson : Arizona Oncology Associates, PC - HOPE
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Arkansas
Hot Springs : Genesis Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Jonesboro : NEA Baptist Clinic
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Little Rock : Little Rock Hematology Oncology Associates
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
California
Duarte : City of Hope Updated
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR
View More »
Anaheim : Pacific Cancer Medical Center, Inc
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Burbank : US Oncology - Providence Health System, Site #167
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Escondido : Southwest Cancer Care Medical Group
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Glendora : Wilshire Oncology Medical Group, Inc
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
La Jolla : Moores UCSD Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Los Angeles : UCLA Department of Medicine, Site #027
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Los Angeles : University of Southern California
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Orange : Children's Hospital of Orange County CHOC
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Oxnard : PMK Medical Group, Inc. DBA Ventura
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Palo Alto : Stanford University Medical Center Oncology
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Pleasant Hill : Bay Area Cancer Research Group, Site #157
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Pleasant Hill : Bay Area Cancer Research Group, Site #156
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
San Francisco : University of California Medical Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Colorado
Boulder : Rocky Mountain Cancer Centers, Site #191
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Boulder : Rocky Mountain Cancer Centers
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Connecticut
Manchester : Medical Oncology and Blood Disorders, LLP
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Southington : Cancer Center of Central Connecticut, Site #147
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Delaware
Newark : Christiana Care Health Services, Site #155
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Florida
Boynton Beach : University Cancer Institute, Site #149
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Boynton Beach : Hematology And Medical Oncology Of Southern Palm Beach County
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Fort Myers : Florida Cancer Specialists, Site #180
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Hialeah : Palm Springs Research Institute
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Jacksonville : Baptist Cancer Institute
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
View More »
Jacksonville : University Of Florida
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Lakeland : Watson Clinic
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Miami : University of Miami
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
New Port Richey : Florida Cancer Specialists
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Orlando : Cancer Centers of Florida
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
St. Petersburg : Florida Cancer Specialists, Site #179
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Tavares : Lake County Oncology and Hematology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Titusville : Space Coast Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Georgia
Atlanta : Emory University, Site #058
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Atlanta : Emory University
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Marietta : Northwest Georgia Oncology Centers, PC
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Sandy Springs : Georgia Cancer Specialist
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Hawaii
Honolulu : OnCare
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Honolulu : Straub Clinical & Hospital
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Illinois
Chicago : Ann & Robert H. Lurie Children's Hospital of Chicago Ann&Robert Lurie
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Chicago : University of Chicago, Site #001
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Evergreen Park : Mahafzah Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Maywood : Loyola University Chicago, Site #054
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Maywood : Loyola University Medical Center, Cardinal Bernardin Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
View More »
Niles : Orchard Health Care Research
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Normal : Mid-Illinois Hem/Onc Asoc
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
North Chicago : North Chicago VA Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Springfield : Southern Illinois School of Medicine
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Indiana
Anderson : Saint John's Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Beech Grove : Indiana Blood and Marrow Institute SC
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Beech Grove : Indiana Blood and Marrow Transplantation, LLC
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Indianapolis : Indiana University Riley Hospital for Children
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Indianapolis : Franciscan St. Francis Health, Site #138
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
View More »
Indianapolis : Indiana Blood and Marrow Transplantation
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Indianapolis : Investigative Clinical Research of Indiana
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
New Albany : Cancer Care Center, Inc. PC
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Iowa
Iowa City : University of Iowa Hospitals and Clinics, Site #050
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Mason City : N. Iowa Mercy Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Kansas
Hutchinson : Hutchinson Clinic
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Topeka : Cotton O'Neil Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Wichita : US Oncology - Cancer Center of Kansas, Site #168
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Wichita : Cancer Center of Kansas
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Kentucky
Lexington : Central Baptist Hospital
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Louisiana
Shreveport : Willis-Knighton Cancer System
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Maryland
Baltimore : St. Agnes Hospital SC
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Baltimore : University of Maryland, Greenebaum Cancer Center, Site #040
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Baltimore : Greater Baltimore Medical Center, Site #140
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Columbia : Maryland Oncology Hematology Pa
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Massachusetts
Boston : Dana Farber Cancer Institute, Site #008
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Boston : Massachusetts General Hospital, Site #047
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Boston : Boston VA Healthcare System
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Quincy : Commonwealth Hematology-Oncology, P.C.
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Worcester : University of Massachusetts Memorial Medical Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Michigan
Ann Arbor : University of Michigan Medical Center, Site #011
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Kalamazoo : West Michigan Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Lansing : Michigan State University
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Minnesota
Minneapolis : University of Minnesota
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Rochester : Mayo Clinic, Site #044
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Missouri
Kansas City : Saint Luke's Hospital, Site #162
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Springfield : Mercy Clinic - Cancer & Hematology, Site #151
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Springfield : St John's Clinic for Cancer and Hematology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Montana
Billings : Billings Clinic
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Nebraska
Lincoln : Nebraska Hematology-Oncology, P.C., Site # 133
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Omaha : Omaha VAMC
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Nevada
New Hampshire
Portsmouth : Portsmouth Regional Hospital
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
New Jersey
Hackensack : John Theurer Cancer Center, Site #128
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Hackensack : Hackensack University Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Morristown : Hematology-Oncology Associates of Northern NJ, PA
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Vineland : Southern Oncology Hematology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
New Mexico
Albuquerque : University of New Mexico Cancer Center, Site #166
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
New York
Bronx : Montefiore Medical Center / AECOM
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Johnson City : Broome Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Mineola : Winthrop University Hospital, Site #153
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
New York : Memorial Sloan Kettering Cancer Center
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
New York : Weill Cornell Medical College, Site #006
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
View More »
New York : Memorial Sloan-Kettering Cancer Center, Site #078
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
New York : St. Lukes Roosevelt Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
New York : Advanced Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Stony Brook : Stony Brook University Hospital
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Valhalla : New York Medical College, Site #146
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
North Carolina
Cary : Waverly Hematology Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Charlotte : Levine Children's Hospital
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Durham : Duke University Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Gastonia : Gaston Hematology Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Greenville : East Carolina University
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
View More »
Raleigh : Rex Cancer Center - Wakefield
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Raleigh : Rex Cancer Center
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Ohio
Akron : Akron General Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Cincinnati : Cincinnati Children's Hospital Medical Center Cincinnati Children's Hosp
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Cleveland : Cleveland Clinic
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Middletown : Signal Point Clinical Research Center, Site #139
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Middletown : Signal Point Clinical Research Center, LLC
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
View More »
Newark : Medical Center of Newark
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Oklahoma
Oklahoma City : University of Oklahoma, Site #028
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Tulsa : Cancer Care Associates
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Oregon
Portland : Oregon Health & Science University, Site #048
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Portland : Oregon Health & Science University
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Salem : Hematology/Oncology Salem LLP
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Pennsylvania
Gettysburg : Gettysburg Cancer Center, Site #160
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Kingston : Medical Oncology Associates of Wyoming Valley, PC
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Lancaster : Lancaster General Health
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Norristown : Luitpold Pharmaceuticals, Inc.
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Philadelphia : Children's Hospital of Philadelphia Pediatric Oncology Clinic
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
View More »
Pittsburgh : Western Pennsylvania Hospital, Site #159
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Pittsburgh : The Western Pennsylvania Hospital
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Pittsburgh : Veterans Research Foundation of Pittsburgh
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Wilkes-Barre : Geisinger Health System
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
York : Cancer Care Association Of York
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Rhode Island
Cranston : Hematology and Oncology Associates of RI
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
South Carolina
Charleston : Medical University of South Carolina, Site #148
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Charleston : Charleston Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Sumter : Carolina Hematology Oncology, Site #143
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
South Dakota
Sioux Falls : Avera Research Institute
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Watertown : Prairie Lakes Healthcare System, Inc
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Tennessee
Knoxville : Tennessee Cancer Specialists
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Nashville : Sarah Cannon Research Institute
A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene
Nashville : Sarah Cannon Research Institute, Site #076
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Texas
Amarillo : Texas Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Arlington : Texas Oncology - Arlington South
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Austin : US Oncology - Texas Oncology Austin, Site #172
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Austin : Texas Oncology-Austin North
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Beaumont : Julie & Ben Rogers Cancer Institute
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
View More »
Dallas : US Oncology - Texas Oncology Dallas, Site #171
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Dallas : Texas Oncology-Dallas Presbyterian Hospital
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Dallas : Texas Oncology-Methodist Charlton Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Dallas : Texas Oncology-Medical City Dallas
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Houston : University of Texas M.D. Anderson Cancer Center
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
Houston : The University of Texas MD Anderson Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Houston : MD Anderson Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Houston : Michael DeBakey VA Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Lewisville : Texas Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
McAllen : Texas Oncology-McAllen South Second
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Mesquite : Texas Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Midland : US Oncology - Texas Oncology Midland, Site #173
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Midland : Texas Oncology-Midland Allison Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Odessa : Texas Oncology-Odessa West Texas Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Paris : Texas Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Plano : North Texas Regional Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
San Antonio : US Oncology - Cancer Care Center of South Texas, Site #170
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
San Antonio : Cancer Care Centers of South Texas
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Waco : Texas Oncology
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Utah
Salt Lake City : Huntsman Cancer Institute, Site #043
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Virginia
Fredericksburg : Hematology Oncology Associates of Fredricksburg
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Newport News : Peninsula Cancer Institute
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Roanoke : Blue Ridge Cancer Care
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Washington
Seattle : Seattle Cancer Care Alliance, Site #100
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Spokane : Providence Cancer Center at Sacred Heart Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Vancouver : US Oncology - Northwest Cancer Specialists, Site #174
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Wenatchee : Wenatchee Valley Medical Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Yakima : Yakima Valley Memorial Hospital/North Star Lodge
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
AP24534 - A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adults with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
View More »
Martinsburg : City Hospital - West Virginia University Hospital East
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Morgantown : West Virginia University, Site #154
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Wheeling : Wheeling Hospital
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Wisconsin
Wausau : Aspirus Regional Cancer Center
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Argentina
Buenos aires : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Buenos Aires : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Rio Negro : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Australia
Adelaide : Royal Adelaide Hospital, Site #951
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
East Melbourne : The Peter MacCallum Cancer Center, Site #950
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Garran : Canberra Hospital, Site #971
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Melbourne : Box Hill Hospital, Site #940
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Perth : Royal Perth Hospital, Site #972
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Belgium
Brazil
Barretos : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Curitiba : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Goiania : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Porto Alegre : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Porto Alegre : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
View More »
Salvador : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Sao Paulo : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
São Paulo : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Canada
Hamilton : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Montreal : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Montreal : Jewish General Hospital, Site #129
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Québec : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Saskatoon : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
View More »
Toronto : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Toronto : University Health Network, Princess Margaret Hospital, Site #083
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Vancouver : Leukemia BMT program of BC, Vancouver General Hospital, Hematology Research and Clinical Trials Unit
A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib
China
Shanghai : Shanghai Jiaotong University School of Medicine Ruijin Hospital
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Czech Republic
Hradec Kralove : FN Hradec Kralove, Site #517
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Finland
Helsinki : Helsinki University Central Hospital, Site #542
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
France
Bordeaux : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Bordeaux : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Bordeaux : Institut Bergonie, Site #772
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Le Chesnay Cedex : Centre Hospitalier de Versailles, Site #958
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Lille cedex : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
View More »
Lille Cedex : Hospital Claude Huriez, Site #952
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Nancy Cedex : CHU de Brabois, Site #953
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Paris : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Paris : Hospital Saint Antoine, Site #518
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Paris Cedex 19 : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Pierre Benite : Centre Hospitalier Lyon Sud, Site #956
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Pierre Benite : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Pierre-Benite Cédex : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Poitiers : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Poitiers : CHU de Poitiers, Site #954
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Vandoeuvre les Nancy : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Germany
Aachen : Universitätsklinikum Aachen, AÖR, Site #513
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Amberg : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Aschaffenburg : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Baden-Baden : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Bamberg : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
View More »
Berlin : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Berlin : Charite - Universitatsmedizin Berlin, Site #701
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Bottrop : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Dresden : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Dresden : Universitatsklinikum Carl Gustav Carus an der TU Dresden, Site #526
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Essen : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Frankfurt am Main : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Frankurt am Main : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Freiburg : Universitatsklinikum Freiburg, Site #527
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Hamburg : Universitatsklinikum Hamburg-Eppendorf, Site #524
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Hof : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Jena : Universitatsklinikum Jena, Site #946
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Koblenz : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Koln : Universitatsklinikum Koln-AOR, Site #525
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Köln : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Landshut : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Leipzig : Novartis Investigative Site
Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
Mannheim : Universitat Heidelberg, CML - Studienzentrale III. Medizinische Klinik, Site #947
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Mülheim a. d. Ruhr : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Munchen : Klinikum rechts der Isar, Site #949
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Offenbach : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Potsdam : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Rostock : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Rötha : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Singen : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Soest : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Ulm : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Weiden : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Hong Kong
Hong Kong : Queen Mary Hospital, Site #973
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Israel
Jerusalem : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Ramat Gan : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Italy
Bari : Unita Operativa di Ematologia con Trapianto, Site #529
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Bologna : Istituto di Ematologia "L. & A. Seragnoli", Site #959
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Catania : A.O. Universitaria Policlinico Vittorio Emanuele di Catania, Site #530
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Genova : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Genova : Clinica Ematologica, Site #528
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
View More »
Milan : Ospedale Niguarda Ca' Granda di Milano, Site #531
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Milan : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Milano : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Modena : S.C. Ematologia, Site #960
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Monza : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Monza : San Gerardo Hospital, Site #961
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Napoli : Universita Federico II, Site #510
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Orbassano : SCDU Medicina Interna II - Indirizzo Ematologico, Site #785
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Padova : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Roma : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Japan
Nagoya : Updated
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Tokyo : Updated
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
Korea, Republic of
Seocho-gu : The Catholic University of Korea, Site #938
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Seoul : Seoul St. Mary's Hospital
Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib
Netherlands
Amsterdam : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Amsterdam : VU Medical Centre - Department Haematology, Site #948
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Hoofddorp : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Rotterdam : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
New Zealand
Christchurch : Christchurch Hospital, Site #922
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Grafton : Auckland City Hospital, Site #921
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Hamilton : Waikato Hospital, Site #977
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Takapuna : North Shore Hospital, Site #976
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Puerto Rico
Bayamon : Puerto Rico Hematology Oncology Group
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Russian Federation
Arkhangelsk : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Ekaterinburg : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Irkutsk : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Moscow : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Nizhnii Novgorod : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
View More »
Perm : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Rostov-on-Don : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Ryazan : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Saint-Petersburg : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
St Petersburg : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
St Petersburg : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
St Petersburg : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Tula : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Singapore
Singapore : Singapore General Hospital, Site #939
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Slovakia
Bratislava : Narodny onkologicky ustav, Site #532
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Martin : Univerzitna nemocnica Martin, Site #533
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Spain
A Coruna : Complejo Hospitalario Universitario A Coruna, Hospital "Teresa Herrera," Site #554
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Alicante : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Badalona : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Badalona : Hospital Universitari Germans Trias i Pujol, Site #512
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Barcelona : Hospital Clinic, Site #963
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
View More »
Girona : Institut Catala d' Oncologia de Girona, S. de Hematologia Clinica, Site #734
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Islas Baleares : Hospital Universitari Son Espases, Site #553
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Madrid : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Madrid : Hospital Gregorio Maranon, Site #536
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Madrid : Hospital Universitario 12 de Octubre, Site #537
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Madrid : H.U. Ramon y Cajal, Site #538
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Madrid : Hospital La Paz, Site #966
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Oviedo : Hospital Universitario Central de Asturias, Site #535
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Salamanca : Hospital Universitario de Salamanca, Site #965
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Santiago de Compostela-A Coruña : Local Institution
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Sevilla : Novartis Investigative Site
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Valencia : Hospital Clinico Universitario de Valencia, Site #964
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Sweden
Lund : Skane University Hospital, Site #944
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Stockholm : Karolinska University Hospital Solna, Site #763
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Stockholm : Karolinska University Hospital Huddinge, Site #534
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Uppsala : Uppsala University Hospital, Site #945
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Switzerland
Aarau : Kantonsspital Aarau, Site #541
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Taiwan
Lin-Ko : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Niaosong Township : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Taiching : China Medical University Hospital, Site #978
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Taipei : National Taiwan University Hospital, Site #979
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Taipei : Novartis Investigative Site
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Thailand
Bangkok : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
United Kingdom
Birmingham : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Bristol : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Glasgow : University of Glasgow, Site #797
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Glasgow : Novartis Investigative Site
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
Leeds : St. James University Hospital, Site #540
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
View More »
Liverpool : Royal Liverpool University Hospital, Site #969
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
London : Hammersmith Hospital, Site #967
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Manchester : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Newcastle : Newcastle University, Site #970
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Nottingham : Nottingham University Hospitals NHS Trust, Site #968
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Oxford : Oxford University Hospitals NHS Trust, Site #543
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Sutton : Novartis Investigative Site
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)